Eloxx Pharmaceuticals, Inc.

NasdaqCM:ELOX Stock Report

Market Cap: US$63.6m

Eloxx Pharmaceuticals Future Growth

Future criteria checks 0/6

Eloxx Pharmaceuticals's earnings are forecast to decline at 30.1% per annum. EPS is expected to grow by 0.3% per annum.

Key information

-30.1%

Earnings growth rate

0.35%

EPS growth rate

Pharmaceuticals earnings growth18.7%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

Low

Last updated11 Sep 2026

Recent future growth updates

Recent updates

Seeking Alpha • Sep 14

Eloxx says lead asset failed in mid-stage cystic fibrosis trial

Eloxx Pharmaceuticals (NASDAQ:ELOX), a company focused on rare diseases, announced Wednesday that its lead candidate, ELX-02 in combination with ivacaftor, did not achieve efficacy endpoints in a Phase 2 trial involving certain patients with cystic fibrosis (CF). ELOX shares are currently on hold for trading. The study evaluated ELX-02 as monotherapy in combination with ivacaftor in Class 1 CF patients with at least one nonsense genetic mutation. According to topline data, the drug was well tolerated with no treatment-related serious adverse events. However, the trial did not achieve statistical significance for efficacy endpoints, including changes in sweat chloride concentration (SCC) and percent forced expiratory volume (FEV1) from the baseline. Given the safety and signs of clinical activity, ELOX, as previously announced, plans to start a proof-of-concept trial for ELX-02 later this year, targeting patients with the rare kidney disease, Alport syndrome.
Seeking Alpha • Aug 15

Eloxx Pharmaceuticals GAAP EPS of -$0.12 in-line

Eloxx Pharmaceuticals press release (NASDAQ:ELOX): Q2 GAAP EPS of -$0.12 in-line. As of June 30, 2022, Eloxx had unrestricted cash and cash equivalents of $30.0M. "As of June 30, 2022, the Company was in compliance with all debt covenants. If our lender does not accelerate our debt upon our failure to comply with the minimum cash covenant, we expect our current cash position will be sufficient to fund our operations into the fourth quarter of 2023," the company statement.
Analysis Article • Sep 09

Is Eloxx Pharmaceuticals (NASDAQ:ELOX) Using Debt In A Risky Way?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Feb 17

What Kind Of Investors Own Most Of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX)?

The big shareholder groups in Eloxx Pharmaceuticals, Inc. ( NASDAQ:ELOX ) have power over the company. Institutions...

Earnings and Revenue Growth Forecasts

NasdaqCM:ELOX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2028N/A-42-37-442
12/31/2027N/A-36-26-332
12/31/2026N/A-18-5-192
6/30/2026N/A-11-16-16N/A
3/31/2026N/A-8-13-13N/A
12/31/2025N/A-6-6-6N/A
12/31/20246-3-5-5N/A
12/31/2023N/A-17-14-14N/A
9/30/2023N/A-20-18-18N/A
6/30/2023N/A-24-22-21N/A
3/31/2023N/A-31-29-29N/A
12/31/2022N/A-36-32-32N/A
9/30/2022N/A-42-36-36N/A
6/30/2022N/A-44-37-37N/A
3/31/2022N/A-70-37-37N/A
12/31/2021N/A-67-35-35N/A
9/30/2021N/A-61-30-30N/A
6/30/2021N/A-57-27-27N/A
3/31/2021N/A-29-24-24N/A
12/31/2020N/A-35-28-28N/A
9/30/2020N/A-40-33-33N/A
6/30/2020N/A-46-39-39N/A
3/31/2020N/A-53N/A-42N/A
12/31/2019N/A-51N/A-39N/A
9/30/2019N/A-53N/A-39N/A
6/30/2019N/A-52N/A-36N/A
3/31/2019N/A-51N/A-35N/A
12/31/2018N/A-47N/A-31N/A
9/30/2018N/A-45N/A-29N/A
6/30/2018N/A-38N/A-24N/A
3/31/2018N/A-29N/A-19N/A
12/31/2017N/A-24N/A-16N/A
9/30/2017N/A-16N/A-14N/A
12/31/2016N/A-11N/A-9N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ELOX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ELOX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ELOX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if ELOX's revenue is forecast to grow faster than the US market.

High Growth Revenue: ELOX is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ELOX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/13 02:48
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Eloxx Pharmaceuticals, Inc. is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yun ZhongBrean Capital Historical (Janney Montgomery)
Mayank MamtaniB. Riley Securities, Inc.
Arlinda LeeCanaccord Genuity